Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
COLORADO SPRINGS, Colo., Nov. 07, 2016 -- The Spectranetics Corporation (NASDAQ:SPNC), (“the Company”) today announced that company management will be attending three upcoming investor conferences.
On November 16th, 2016, the Company will attend the Stifel Healthcare Conference at the Lotte New York Palace Hotel. The fireside chat will begin at 8:45 am Eastern Standard Time and can be accessed via the live webcast at http://wsw.com/webcast/stifel5/spnc.
On November 17th, 2016, the Company will attend the Canaccord Genuity Medical Technologies & Diagnostics Forum. The fireside chat will begin at 10 am Eastern Standard Time and can be accessed via the live webcast at http://wsw.com/webcast/canaccord24/spnc.
Additionally, on November 30th, 2016, the Company will attend the 28th Annual Piper Jaffray Healthcare Conference. Webcasting details will be available two weeks prior to the event.
Access to each of the three webcasts will also be available in the Events section of the Investor Relations website at http://www.spectranetics.com/investor-relations/investor-events.
About Spectranetics
The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are available in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
Investor Relations Contacts Zach Stassen Sr. Director of Finance [email protected] (719) 447-2292 Michaella Gallina Director of Investor Relations [email protected] (719) 447-2417
